PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of bttDove Medical PressThis ArticleSubscribeSubmit a ManuscriptSearchFollowDovepressBiologics: Targets and Therapy
 
From:
Published online 2012 July 2. doi: 10.2147/BTT.S20659

Table 1

Radiographic outcomes reported in clinical trials for biologic combination therapy with methotrexate or as monotherapy at baseline and at 52 weeks

Baseline X-ray scoreMean change in X-ray scoreP value


MTXBiologic + MTXMTXBiologic + MTX
Agent + methotrexate
Infliximab1382754.00.25<0.001
Infliximab1425.0−1.57<0.001
Adalimumab1166.472.12.70.1<0.001
Etanercept626.821.82.8−0.54<0.0001
Adalimumab1221.918.15.71.3<0.001
Abatacept2044.944.52.31.20.012
Certolizumab1046.539.61.20.2<0.01
Abatacept216.77.50.631.060.04
Rituximab1632.530.62.811.14<0.0001
Golimumab15,*19.718.71.370.740.015
Golimumab15,*36.729.71.10.930.855
Tocilizumab1928.528.81.130.29<0.0001
Rituximab177.47.70.740.23<0.001
MTXBiologicMTXBiologic

Monotherapy
Etanercept512.92.41.591.000.11
Etanercept2226.821.82.80.520.0469
Adalimumab1221.918.85.73.0<0.001
Tocilizumab1830.628.36.12.3<0.01
Golimumab15,*19.720.41.371.250.266
Golimumab15,*36.737.41.100.890.967

Notes:

*First line of data is from GO-BEFORE and the second is from GO-FORWARD. Not all trials reported data in this format.

Abbreviation: MTX, methotrexate.